2. Search Result
Search Result
Results for "

Lifastuzumab

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

2

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99970
    Lifastuzumab

    		ADC Antibody Others
    Lifastuzumab is a humanized anti-NaPi2b monoclonal antibody (IgG1 type). Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) through ADC Linker to form an antibody-drug conjugate (ADC) lifastuzumab vedotin (DNIB0600A) with anticancer activity .
    Lifastuzumab
  • HY-P99705
    Lifastuzumab vedotin

    RG-7599; DNIB-0600A; NaPi2b-ADC

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Lifastuzumab vedotin (RG-7599; DNIB0600A) is an antibody-drug conjugate (ADC) that comprises a humanized IgG1 anti-NaPi2b monoclonal antibody (MNIB2126A) and a potent antimitotic agent, monomethyl auristatin E (MMAE), which inhibits cell division by blocking the polymerization of tubulin. Lifastuzumab vedotin has the potential for non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC) research .
    Lifastuzumab vedotin
  • HY-171737
    Anti-SLC34A2 (Lifastuzumab)-McMMAF

    		Antibody-Drug Conjugates (ADCs) Sodium Channel Microtubule/Tubulin Apoptosis Cancer
    Anti-SLC34A2 (Lifastuzumab)-McMMAF is an antibody-drug conjugate (ADC) consisting of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab (HY-P99970) conjugated to the protective group maleimidocaproyl and the tubulin inhibitor MMAF (HY-15579). The ADC toxic molecule and linker part McMMAF (HY-15578). Anti-SLC34A2 (Lifastuzumab)-McMMAF induces apoptosis and can be used in cancer research .
    Anti-SLC34A2 (Lifastuzumab)-McMMAF
  • HY-171735
    Anti-SLC34A2 (Lifastuzumab)-SMCC-DM1

    		Antibody-Drug Conjugates (ADCs) Sodium Channel Microtubule/Tubulin Cancer
    Anti-SLC34A2 (Lifastuzumab)-SMCC-DM1 is an antibody-drug conjugate (ADC) consisting of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab (HY-P99970) conjugated to the linker SMCC (HY-42360) and the the cytotoxic microtubule inhibitor DM1 (HY-19792). The ADC toxic molecule and linker part are SMCC-DM1 (HY-101070). Anti-SLC34A2 (Lifastuzumab)-SMCC-DM1 can be used in the research of cancer .
    Anti-SLC34A2 (Lifastuzumab)-SMCC-DM1
  • HY-171736
    Anti-SLC34A2 (Lifastuzumab)-SPDB-DM4

    		Antibody-Drug Conjugates (ADCs) Sodium Channel Microtubule/Tubulin Cancer
    Anti-SLC34A2 (Lifastuzumab)-SPDB-DM4 is an antibody-drug conjugate (ADC) consisting of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab (HY-P99970) conjugated with the linker SPDB (HY-12448) and the tubulin inhibitor DM4 (HY-12454). The ADC toxic molecule and linker part are sulfo-SPDB-DM4 (HY-101141). Anti-SLC34A2 (Lifastuzumab)-SPDB-DM4 can be used in cancer research .
    Anti-SLC34A2 (Lifastuzumab)-SPDB-DM4
  • HY-171738
    Anti-SLC34A2 (Lifastuzumab)-MC-Vc-PAB-SN38

    		Antibody-Drug Conjugates (ADCs) Topoisomerase Sodium Channel Cancer
    Anti-SLC34A2 (Lifastuzumab)-MC-Vc-PAB-SN38 is an antibody-drug conjugate (ADC) consisting of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab (HY-P99970) conjugated to the linker Mc-VC-PAB and the topoisomerase I inhibitor SN38 (HY-13704). The ADC toxic molecule and linker part are Mc-VC-PAB-SN38 (HY-131057). Anti-SLC34A2 (Lifastuzumab)-MC-Vc-PAB-SN38 can be used in cancer research .
    Anti-SLC34A2 (Lifastuzumab)-MC-Vc-PAB-SN38

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: